newsfilter
← Latest News
Business Wire·

bluebird bio Reports First Quarter 2024 Results and Highlights Operational Progress and 2024 Guidance

- First patient start (cell collection) for LYFGENIA completed – - 15 patient starts to date in 2024 (11 ZYNTEGLO, 3 SKYSONA, 1 LYFGENIA); 85 to 105 patient starts anticipated across the portfolio in 2024 - - First